$59.20 -0.07 (%) Seattle Genetics Inc - NASDAQ

Jan. 20, 2017 | 12:50 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Trump Twitter Hangover Keeps Biotech Stocks Down

    TalkMarkets | Jan. 19, 2017 | 01:30AM EST
  2. What Does SGEN's Clinical Hold On CD33A Mean For Actinium?

    TalkMarkets | Jan. 4, 2017 | 17:35PM EST
  3. Seattle Genetics CEO Angles For Hodgkin's Lymphoma Eureka: Exclusive

    Investors Business Daily | Dec. 29, 2016 | 07:30AM EST
  4. Seattle Genetics Gets Price-Target Cut On FDA News, But Shares Up

    Investors Business Daily | Dec. 28, 2016 | 12:25PM EST
  5. The Dow Jones Industrial Average Once Again Flirted With The Widely-Watched 20,000 Level

    TalkMarkets | Dec. 28, 2016 | 01:00AM EST
  6. Seattle Genetics Receives FDA Halt On Several Phase 1 Studies

    TalkMarkets | Dec. 27, 2016 | 09:40AM EST
  7. Seattle Genetics Leukemia Drug Trials Halted, Stock Plunges

    Investors Business Daily | Dec. 27, 2016 | 09:03AM EST
  8. Gilead Buying Alexion Tops Piper's Potential Events In 2017

    TalkMarkets | Dec. 21, 2016 | 08:36AM EST
  9. Morning Call For Monday, Dec. 12

    TalkMarkets | Dec. 12, 2016 | 08:25AM EST
  10. Biotechs Unhinged By Tough Pricing Talk

    TalkMarkets | Dec. 8, 2016 | 23:04PM EST
  11. Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC

    Investors Business Daily | Dec. 1, 2016 | 14:14PM EST
  12. Alert: Alzheimer’s Drug Fails In Clinical Trial - Stocks Sink

    TalkMarkets | Nov. 24, 2016 | 00:03AM EST
  13. Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech?

    TalkMarkets | Nov. 23, 2016 | 00:13AM EST
  14. Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

    TalkMarkets | Nov. 9, 2016 | 23:23PM EST
  15. Biotech Meltdown: Financial Metrics Offer Few Clues For What is Next

    TalkMarkets | Nov. 1, 2016 | 06:52AM EST
  16. Seattle Genetics (SGEN) Loss Narrower Than Expected In Q3

    TalkMarkets | Oct. 29, 2016 | 19:13PM EST
  17. Comparing Actinium's Actimab-A To Seattle Genetics' SGN-CD33A

    TalkMarkets | Oct. 11, 2016 | 17:40PM EST
  18. Apple Upgraded; Twitter A 'Loser'; Caterpillar Price Target Hiked

    Investors Business Daily | Jul. 27, 2016 | 08:25AM EST
  19. Benzinga's Top Upgrades

    Benzinga | Feb. 10, 2016 | 08:55AM EST
  20. Benzinga's Top Initiations

    Benzinga | Feb. 4, 2016 | 09:56AM EST
  21. 4 Stocks Moving On Breast-Cancer News

    IBD | Dec. 10, 2015 | 16:04PM EST
  22. Seattle Genetics Highlights Data from SGN-CD19A Antibody-Drug Conjugate Program at #ASH2015

    Benzinga | Dec. 6, 2015 | 08:42AM EST
  23. Benzinga's Top Upgrades

    Benzinga | Oct. 30, 2015 | 08:10AM EST
  24. Here's Why Biotechs Fell On Monday

    Benzinga | Oct. 19, 2015 | 15:29PM EST
  25. Seattle Genetics Initiates Phase 2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

    Benzinga | Oct. 19, 2015 | 07:00AM EST
  26. Insiders Are Buying Barnes & Noble

    GuruFocus | Sep. 18, 2015 | 17:43PM EST
  27. Seattle Genetics Prices ~11.707M Share Offering of Common Stock @$41.00/Share

    Benzinga | Sep. 10, 2015 | 18:16PM EST
  28. Vanguard Health Care Fund Buys Two New Stakes in Second Quarter

    GuruFocus | Aug. 6, 2015 | 17:14PM EST
  29. Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting

    Benzinga | Jun. 1, 2015 | 09:47AM EST
  30. Insiders keep on buying Macerich Co and Seattle Genetics

    GuruFocus | May. 22, 2015 | 16:46PM EST
  31. Earnings Scheduled For February 10, 2015

    Benzinga | Feb. 10, 2015 | 04:42AM EST
  32. From Coca-Cola To Tesla, Here Are The 68 Most Important Earnings Expectations For The Week

    Benzinga | Feb. 8, 2015 | 10:43AM EST
  33. 10 Biotech Stories You Might've Missed This Week

    Benzinga | Jan. 15, 2015 | 13:18PM EST
  34. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  35. New Biotech ETF From ALPS

    Benzinga | Jan. 2, 2015 | 08:05AM EST
  36. 5 Health Care Stocks Hurting From The Affordable Care Act

    Benzinga | Nov. 4, 2014 | 20:46PM EST
  37. Seattle Genetics: Can Record Growth From Its Licenses

    GuruFocus | Oct. 28, 2014 | 14:50PM EST
  38. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 15:58PM EST
  39. Benzinga's Top Downgrades

    Benzinga | Sep. 30, 2014 | 08:00AM EST
  40. Bank of America Downgrades Seattle Genetics To Underperform

    Benzinga | Sep. 30, 2014 | 07:38AM EST
  41. Seattle Genetics Offers Updated Progression-Free Survival, Overall Survival Data from ADCETRIS Frontline PTCL Phase 1 Trial

    Benzinga | Sep. 24, 2014 | 08:01AM EST
  42. Seattle Genetics: Can Record Sustained Growth From Royalty

    GuruFocus | Aug. 31, 2014 | 13:33PM EST
  43. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus | Jul. 30, 2014 | 18:21PM EST
  44. UPDATE: UBS Upgrades Seattle Genetics

    Benzinga | Jul. 9, 2014 | 10:44AM EST
  45. Target And Others Insiders Have Been Buying

    Benzinga | Jun. 8, 2014 | 13:30PM EST
  46. UPDATE: Bank Of America Upgrades Seattle Genetics

    Benzinga | May. 6, 2014 | 08:31AM EST
  47. UPDATE: Bank of America Upgrades Seattle Genetics On Trial Risks

    Benzinga | May. 6, 2014 | 08:06AM EST
  48. Benzinga's Top Upgrades

    Benzinga | May. 6, 2014 | 06:57AM EST
  49. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga | May. 6, 2014 | 06:29AM EST
  50. Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS

    Benzinga | Apr. 8, 2014 | 08:02AM EST
Trading Center